Pulmonx

Pulmonx Corp. engages in the provision of interventional pulmonology, planning tools and treatments for obstructive lung diseases. It carries out its operations in the following geographical locations: Europe, Middle East and Africa (EMEA), Asia Pacific, Other International and United States. The firm offers the Zephyr Endobronchial Valve, an implantable device used to occlude all airways feeding the hyperinflated lobe of a lung that is most diseased with emphysema. It also offers StratX Lung Analysis, a platform designed to treat severe emphysema and the Chartis Assessment System, a pulmonary assessment system. The company was founded by Rodney C. Perkins in December 1995 and is headquartered in Redwood City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pulmonx reports robust sales growth and eyes Japan expansion

Pulmonx shows strong sales growth and margin improvement in 2022
Balancing expenses and growth focus while navigating regulatory challenges
Confidence in future revenue growth through market expansion and account productivity

Pulmonx reports stellar Q1 sales growth and strategic initiatives

Pulmonx's Q1 2023 performance reflects robust sales growth, strategic commercial initiatives, and a focus on customer engagement. While challenges in profitability persist, the company's strong financial position and confidence in its strategy bode well for future growth and operational efficiency.

Pulmonx reports record sales in Q2 2023, eyes international expansion

Pulmonx delivered strong sales growth in Q2 2023, with a focus on strategic expansion and market development.
While facing financial challenges and losses, the company's emphasis on operational efficiency and international expansion presents growth opportunities.
With an updated revenue guidance and solid gross margin, Pulmonx is poised for continued growth and market penetration in the respiratory device sector.

Pulmonx achieves record revenue, eyes international expansion and patient outcomes

Pulmonx reported strong revenue growth in Q3 2023, driven by U.S. sales and a focus on commercial strategy, with increased account productivity and new center openings.
While facing challenges in international sales and regulatory differences in Europe, the company remains optimistic about future growth and the potential of the AeriSeal program.
Opportunities lie in international expansion, positive patient outcomes expected from the CONVERT 2 study, and investments in the right people and referral centers for enhanced patient care.

Pulmonx reports record sales in Q4 2023, eyes revenue growth

Pulmonx's strong financial performance in Q4 2023 and full year 2023 reflects growth and potential.
The company's strategic focus on product development and market expansion presents opportunities for future revenue.
Challenges include increased R&D expenses and market penetration efforts.
Overall, Pulmonx's performance and future plans indicate a positive outlook for growth and innovation.

Pulmonx reports robust Q1 earnings, eyes global expansion for growth

Pulmonx's strong Q1 performance, focus on innovation, and strategic growth initiatives position the company for long-term success.
While facing challenges in achieving profitability and managing expenses, Pulmonx's market opportunities and financial discipline are key strengths.
The company's outlook for 2024 remains positive, supported by revenue guidance, operational efficiency, and a commitment to patient care.
Investors should monitor Pulmonx's progress in key trials, international expansion, and financial metrics to assess its growth trajectory.

Pulmonx achieves record sales, focuses on growth and efficiency

Pulmonx reported strong sales growth and operational improvements in Q2 2024, despite a net loss.
The company's focus on expanding patient access and driving workflow efficiencies positions it well for future growth.
While facing financial challenges, Pulmonx has opportunities to enhance profitability through cost management and market expansion.
Overall, Pulmonx's strategic initiatives and performance indicate a positive outlook for the company's future.

Pulmonx posts strong Q3 earnings, eyes global expansion opportunities

Pulmonx delivered strong financial performance in Q3 2024, driven by robust U.S. revenue and international growth, positioning the company for future success.
With a focus on innovation, market expansion, and financial discipline, Pulmonx is well-positioned to capitalize on growth opportunities and navigate challenges effectively.
The company's solid cash position, successful clinical trials, and strategic initiatives underscore its potential for sustained growth and market leadership.
Pulmonx's commitment to training, automation, and awareness building, coupled with global expansion plans, bodes well for long-term value creation and competitive advantage.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pulmonx Corp. is a medical technology company, which engages in the provision of interventional pulmonology, planning tools and treatments for obstructive lung diseases. It operates through the United States, Europe, Middle East, Africa, Asia Pacific, and Other International segments. The company was founded by Rodney Perkins on December 26, 1995 and is headquartered in Redwood City, CA.

Pulmonx Corporation (LUNG) CEO Glen French on Q1 2021 Results - Earnings Call Transcript

REDWOOD CITY, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for severe lung disease, today reported financial results for the first quarter ended March 31, 2021.

Pulmonx Reports First Quarter 2021 Financial Results

REDWOOD CITY, Calif., April 20, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2021 after the close of trading on Tuesday, May 4, 2021. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.

Pulmonx to Report First Quarter 2021 Financial Results on May 4, 2021

DraftKings

H&R Block

Novartis

ACADIA Pharma

bluebird bio

Barnes & Noble Education

SNDL Inc.

Vermilion Energy

With the trading day more than halfway over, the broad markets were pushing higher yet again.

DraftKings, H&R Block, Novartis and More Wednesday Afternoon Analyst Calls

Pulmonx Corporation (LUNG) CEO Glendon French on Q4 2020 Results - Earnings Call Transcript

REDWOOD CITY, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year of 2020 ended December 31, 2020.

Pulmonx Reports Fourth Quarter and Full Year 2020 Financial Results

REDWOOD CITY, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2020 after the close of trading on Tuesday, March 2, 2021. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.

Pulmonx to Report Fourth Quarter and Full Year 2020 Financial Results on March 2, 2021

Georgia Garinois-Melenikiotou and Thomas W. Burns Joined the Pulmonx Board in October in Connection with the Company's Initial Public Offering Georgia Garinois-Melenikiotou and Thomas W. Burns Joined the Pulmonx Board in October in Connection with the Company's Initial Public Offering

Pulmonx Welcomes Two New Members to Its Board of Directors, Adding Expertise in Consumer Marketing and Medical Device Company Growth

The Zephyr Valve Helps COPD/Emphysema Patients Breathe Easier Without the Risk of Major Surgery 1

Over 20,000 Patients Treated with the Non-Surgical Zephyr Valve for Severe Emphysema, a Form of COPD

REDWOOD CITY, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a commercial-stage medical technology company that provides minimally invasive treatment for patients with severe emphysema, a form of COPD, today reported financial results for the third quarter ended September 30, 2020.

Pulmonx Reports Third Quarter 2020 Financial Results

REDWOOD CITY, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) today announced the company will be participating in two upcoming virtual investor conferences.

Pulmonx to Present at Upcoming Investor Conferences

Positive Coverage Policy from Health Care Service Corporation (HCSC) Covers Blue Cross Blue Shield Members in Illinois, Montana, New Mexico, Oklahoma and Texas Positive Coverage Policy from Health Care Service Corporation (HCSC) Covers Blue Cross Blue Shield Members in Illinois, Montana, New Mexico, Oklahoma and Texas

Pulmonx Announces Additional 16 Million Covered Lives for The Zephyr® Valve, a Minimally Invasive Treatment Option for Severe Emphysema (COPD)

REDWOOD CITY, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2020 after the close of trading on Tuesday, November 10, 2020. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.

Pulmonx to Report Third Quarter 2020 Financial Results on November 10, 2020

Element Solutions Inc

Selecta Biosciences

Mission Produce

Immunome

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can be an encouraging signal for potential investors, particularly when markets are near all-time highs.

Last Week's Notable Insider Buys: Element Solutions, Selecta Biosciences And More

REDWOOD CITY, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, today announced the closing of its initial public offering of 11,500,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase 1,500,000 additional shares of common stock, at the initial public offering price of $19.00 per share. The gross proceeds to Pulmonx, before deducting underwriting discounts and commissions and offering expenses, were approximately $218.5 million. The shares began trading on The Nasdaq Global Select Market on October 1, 2020, under the symbol "LUNG."

Pulmonx Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Pulmonx: Assessing The IPO

Shares of Pulmonx, a maker of treatments for lung diseases including emphysema, rose 118% in their trading debut Thursday, after the company's initial public offering priced above range. The deal priced at $19 a share, above its proposed price range of $17 to $18.

Pulmonx shares soar 118% in trading debut

Pulmonx, a maker of treatments for lung diseases including emphysema, priced its initial public offering at $19 a share, above its proposed price range of $17 to $18.

Pulmonx prices IPO at $19 a share, above proposed price range

REDWOOD CITY, Calif., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Pulmonx Corporation (“Pulmonx”) today announced the pricing of its upsized initial public offering of 10,000,000 shares of its common stock at a price of $19.00 per share, for gross proceeds of $190,000,000 million, before underwriting discounts and commissions and offering expenses payable by Pulmonx. Pulmonx has also granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All shares are being offered and sold by Pulmonx. The shares are expected to begin trading on the Nasdaq Global Select Market on October 1, 2020 under the ticker symbol “LUNG.” The offering is expected to close on October 5, 2020, subject to the satisfaction of customary closing conditions.

Pulmonx Corporation Announces Pricing of its Upsized Initial Public Offering

Pulmonx, a maker of treatments for lung diseases including emphysema, upsized its planned initial public offering on Wednesday and raised the proposed price range, saying in a regulatory filing it will now offer 10 million shares priced at $17 to $18 each. The company has previously said it would offer 6.7 million shares priced at $14 to $16 each.

News for Pulmonx Stock (LUNG)